Headlines about Bioverativ (NASDAQ:BIVV) have trended somewhat positive on Saturday, according to Accern Sentiment. The research firm identifies negative and positive press coverage by monitoring more than twenty million news and blog sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores closest to one being the most favorable. Bioverativ earned a daily sentiment score of 0.19 on Accern’s scale. Accern also assigned headlines about the biotechnology company an impact score of 46.9617307711938 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the next several days.

These are some of the news headlines that may have effected Accern’s scoring:

Bioverativ (BIVV) opened at 58.08 on Friday. The firm’s 50-day moving average price is $61.09 and its 200-day moving average price is $55.50. The company has a market cap of $6.28 billion and a price-to-earnings ratio of 13.81. Bioverativ has a 52-week low of $41.88 and a 52-week high of $64.41.

Bioverativ (NASDAQ:BIVV) last issued its quarterly earnings data on Wednesday, August 2nd. The biotechnology company reported $0.88 EPS for the quarter, topping analysts’ consensus estimates of $0.71 by $0.17. The business had revenue of $289.10 million during the quarter, compared to the consensus estimate of $269 million. The business’s quarterly revenue was up 37.5% on a year-over-year basis. During the same period last year, the firm earned $0.59 EPS. On average, equities analysts anticipate that Bioverativ will post $2.90 EPS for the current year.

A number of equities research analysts have recently weighed in on BIVV shares. Credit Suisse Group boosted their target price on Bioverativ from $45.00 to $47.00 and gave the company an “underperform” rating in a research note on Monday, May 15th. Jefferies Group LLC reissued a “buy” rating and issued a $70.00 target price (up previously from $67.00) on shares of Bioverativ in a research note on Wednesday. Gabelli lowered Bioverativ from a “buy” rating to a “hold” rating in a research note on Monday, April 24th. They noted that the move was a valuation call. Zacks Investment Research raised Bioverativ from a “hold” rating to a “strong-buy” rating and set a $73.00 price target for the company in a research report on Tuesday, July 25th. Finally, William Blair began coverage on Bioverativ in a research report on Wednesday, June 28th. They set a “market perform” rating for the company. Two research analysts have rated the stock with a sell rating, seven have given a hold rating, five have given a buy rating and one has issued a strong buy rating to the company. The company has an average rating of “Hold” and an average target price of $60.62.

ILLEGAL ACTIVITY NOTICE: “Bioverativ (NASDAQ:BIVV) Earns Daily Media Impact Score of 0.19” was originally published by Daily Political and is the property of of Daily Political. If you are viewing this piece on another publication, it was copied illegally and republished in violation of US and international trademark & copyright legislation. The original version of this piece can be read at https://www.dailypolitical.com/2017/08/11/bioverativ-nasdaqbivv-earns-daily-media-impact-score-of-0-19.html.

In related news, Director Brian S. Posner acquired 1,000 shares of the company’s stock in a transaction dated Wednesday, August 9th. The shares were purchased at an average cost of $59.19 per share, with a total value of $59,190.00. Following the completion of the acquisition, the director now directly owns 6,693 shares of the company’s stock, valued at $396,158.67. The acquisition was disclosed in a filing with the SEC, which can be accessed through this link. Also, Director Brian S. Posner acquired 2,000 shares of the company’s stock in a transaction dated Wednesday, May 24th. The shares were bought at an average cost of $53.86 per share, for a total transaction of $107,720.00. Following the completion of the acquisition, the director now directly owns 4,993 shares of the company’s stock, valued at $268,922.98. The disclosure for this purchase can be found here. Insiders acquired 97,000 shares of company stock worth $5,435,530 over the last ninety days.

About Bioverativ

Bioverativ Inc (Bioverativ) is a biotechnology company. The Company is focused on the discovery, research, development and commercialization of therapies for the treatment of hemophilia and other blood disorders. It markets approximately two products, including ELOCTATE [Antihemophilic Factor (Recombinant), Fc Fusion Protein], and ALPROLIX [Coagulation Factor IX (Recombinant), Fc Fusion Protein], extended half-life clotting-factor therapies for the treatment of hemophilia A and hemophilia B, respectively.

Receive News & Ratings for Bioverativ Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bioverativ Inc and related companies with MarketBeat.com's FREE daily email newsletter.